Table 2.
Experimental design with characteristics of each experimental group.
| Groups | TNBS colitis | DSS colitis | ||||
|---|---|---|---|---|---|---|
| Colitogenic agent | Treatment | N | Colitogenic agent | Treatment | N | |
| N | Saline | Saline s.c. | 30 | Water | Saline s.c. | 15 |
| CNT | TNBS | Saline s.c. | 40 | DSS | Saline s.c. | 20 |
| EphB1-Fc | TNBS | EphB1-Fc s.c. | 10 | DSS | EphB1-Fc s.c. | 6 |
| Ephrin-B1-Fc | TNBS | Ephrin-B1-Fc s.c. | 5 | DSS | Ephrin-B1-Fc s.c. | 5 |
| EphB4 | TNBS | EphB4 s.c. | 15 | DSS | EphB4 s.c. | 6 |
| IgG1-Fc | TNBS | IgG1-Fc s.c. | 6 | DSS | n.d. | n.d. |
| CsA | TNBS | n.d. | n.d. | DSS | Cyclosporine A i.p. | 7 |
N, number of mice in each experimental group; n.d., not determined; TNBS, 2,4,6-trinitrobenzenesulfonic acid; DSS, dextran sulphate sodium; s.c., subcutaneously administered; i.p., intraperitoneally administered.